CN103405501B - Preparation method of three-component blood-activating and stasis-dissolving capsules - Google Patents
Preparation method of three-component blood-activating and stasis-dissolving capsules Download PDFInfo
- Publication number
- CN103405501B CN103405501B CN201310348295.7A CN201310348295A CN103405501B CN 103405501 B CN103405501 B CN 103405501B CN 201310348295 A CN201310348295 A CN 201310348295A CN 103405501 B CN103405501 B CN 103405501B
- Authority
- CN
- China
- Prior art keywords
- capsules
- preparation
- taste
- times amount
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
A preparation method of three-component blood-activating and stasis-dissolving capsules relates to the technical field of medicines, particularly to an improvement on a processing method of the three-component blood-activating and stasis-dissolving capsules. With the following raw materials in parts by weight, the preparation method comprises the steps as follows: (1) extracting salvia miltiorrhiza, filtering and concentrating an extract, adding ethanol to the extract, stirring, standing, collecting supernatant fluid, recycling ethanol, drying and finely grinding; (2) taking leech and lumbricus, adding physiological salt, grinding to obtain homogenate, performing freeze-and-thaw extraction, performing filtration or centrifugation, filtering with an ultrafiltration membrane, concentrating to obtain thick paste, reducing viscosity, stirring uniformly, and drying; (3) mixing the extracts of salvia miltiorrhiza, lumbricus and leech, and obtaining the capsules. The capsules have the advantages of small size, convenience for taking, low price, high efficiency, small dosage, safety and effectiveness, are highly concentrated, have good homogeneity and controllability, are easy for a human body to absorb, are far smaller in dosage than the lowest dosage specified by pharmacopeia, can be used for a long term and can overcome the defect that like oral preparations are not suitable for long-term use.
Description
Technical field
The present invention relates to medical art, be specifically related to the improvement for three taste blood circulation promoting and blood stasis dispelling capsule processing method.
Background technology
The three taste blood circulation promoting and blood stasis dispelling capsules be made up of Radix Salviae Miltiorrhizae, Hirudo and Pheretima, function with cure mainly: blood circulation promoting and blood stasis dispelling, dredge the meridian passage.For the apoplexy apoplex involving the channels and collaterals caused by obstruction of collaterals by blood stasis, disease sees hemiplegia, crooked mouth and tongue, and speech is stuttering puckery or in silence, hemianesthesia, and body of the tongue purple is dim, or has petechia or ecchymosis, deep and hesitant pulse; Cerebral infarction convalescent period sees above-mentioned patient.Specify in Chinese Pharmacopoeia 2010 editions: Radix Salviae Miltiorrhizae consumption 10 ~ 15 grams, Hirudo consumption 1 ~ 3 gram, Pheretima consumption 5 ~ 10 grams.There is large, the effective slow shortcoming of dosage in the medicament that traditional extraction process is extracted, escalated dose is taken, and can strengthen toxic and side effects, there is drug safety problem.
Summary of the invention
Technical problem to be solved by this invention is: for the problems referred to above, provides a kind of improvement of three taste blood circulation promoting and blood stasis dispelling capsule processing method, to improve the medication curative effect of three taste capsules and to take effect.
Technical solution of the present invention is: by weight, comprises the following steps:
(1), get Radix Salviae Miltiorrhizae 300 ~ 700 parts, 12 ~ 24 times amount that add water are extracted, and filter, are concentrated into the clear paste of relative density 1.0 ~ 1.5, add ethanol 2.4 ~ 4.8 times amount, stir, and leave standstill 24 ~ 72 hours, get supernatant, reclaim ethanol and are dried to dry, porphyrize, for subsequent use;
(2), each 80 ~ 120 parts of water intaking trematodiasis, Pheretima add 1 ~ 10 times amount normal saline respectively and soak, and be ground into homogenate, freeze-thaw is extracted, and filters or centrifugal, and filtrate is for subsequent use; Residue extracting in water, filter, filtrate and supernatant merge, and ultrafilter membrane filters, and be concentrated into the thick paste of relative density 1.2 ~ 1.8, viscosity reduction is thick, stirs, and be dried to dry, porphyrize is for subsequent use; Medical material residue is again with ethanol 1 ~ 8 times amount leaching 1 ~ 10 day, and filter, filtrate is concentrated into the thick paste of relative density 1.2 ~ 1.8, and viscosity reduction is thick, stirs, and is dried to dry, porphyrize, for subsequent use;
(3), by Radix Salviae Miltiorrhizae, Pheretima, Hirudo extract merge, add micropowder silica gel 2 ~ 10 parts, add starch and make into 200 ~ 400 parts, stir, incapsulate, to obtain final product.
Technique effect of the present invention is: it has, and volume is little, taking convenience, cheap, effective fast, taking dose is low, advantage safely and effectively, this product high enrichment, the homogeneity of product and controllability good, be beneficial to absorption of human body, using dosage is far smaller than the lowest dose level of States Pharmacopoeia specifications, can long-term taking, and the weakness that similar oral formulations should not take for a long time can be overcome.
Detailed description of the invention
The Main Ingredients and Appearance of three taste blood circulation promoting and blood stasis dispelling capsules comprises Radix Salviae Miltiorrhizae, Hirudo and Pheretima, and concrete preparation method comprises the following steps:
(1), get Radix Salviae Miltiorrhizae 500 parts, 12 ~ 24 times amount that add water are extracted, and filter, are concentrated into the clear paste of relative density 1.0 ~ 1.5, add ethanol 2.4 ~ 4.8 times amount, stir, and leave standstill 24 ~ 72 hours, get supernatant, reclaim ethanol and are dried to dry, porphyrize, for subsequent use;
(2), each 100 parts of water intaking trematodiasis, Pheretima add 1 ~ 10 times amount normal saline respectively and soak, and be ground into homogenate, freeze-thaw is extracted, and filters or centrifugal, and filtrate is for subsequent use; Residue extracting in water, filter, filtrate and supernatant merge, and ultrafilter membrane filters, and filtrate low temperature (4 DEG C ~ room temperature) is concentrated into the thick paste of relative density 1.2 ~ 1.8, and viscosity reduction is thick, stirs, and cold drying is to dry, and porphyrize is for subsequent use; Medical material residue uses ethanol 1 ~ 8 times amount warm macerating 1 ~ 10 day again, and filter, filtrate cryoconcentration is to the thick paste of relative density 1.2 ~ 1.8, and viscosity reduction is thick, stirs, and cold drying is extremely dry, and porphyrize is for subsequent use;
(3), by Radix Salviae Miltiorrhizae, Pheretima, Hirudo extract merge, add micropowder silica gel 2 ~ 10 parts, add starch and make into 300 parts, stir, incapsulate, to obtain final product.
In step (1), extracting in water is 2 times, and add water 6 ~ 12 times amount at every turn, extracts 1 ~ 5 hour.Ethanol described in step (1) is for adding 80% ethanol 1 ~ 6 times amount.In step (1), mixing time is 10 ~ 50 minutes.In step (2), Hirudo, Pheretima add 1 ~ 10 times amount normal saline respectively and soak, and continue and add normal saline 2 times amount, be ground into homogenate.After being ground into homogenate in step (2), jolting is extracted 1 ~ 12 hour.In step (2), freeze-thaw is extracted, and leaves standstill 1 ~ 12 hour.Residue 1 ~ 5 times amount that adds water extracts 2 times, each 1 ~ 3 hour respectively in step (2).50% ethanol 1 ~ 8 times amount lixiviate 1 ~ 10 day of step (2) Chinese crude drug residue.
Specific embodiment:
Get red rooted salvia 500g, extracting in water 2 times, add water 6 ~ 12 times amount at every turn, extract 1 ~ 5 hour, filter, merging filtrate, be concentrated into the clear paste of relative density 1.0 ~ 1.5, add 80% ethanol 3 ~ 6 times amount, stir 50 minutes, leave standstill 24 ~ 72 hours, get supernatant, reclaim ethanol and be dried to dry, porphyrize, for subsequent use.
Water intaking trematodiasis, each 100g medical material of Pheretima add 1 ~ 5 times amount normal saline immersion respectively, continue and add normal saline 2 times amount, are ground into homogenate (jolting is extracted 3 ~ 12 hours), and freeze-thaw is extracted (leaving standstill 12 hours), filtration or centrifugal, and filtrate is for subsequent use; Residue 1 ~ 5 times amount that adds water extracts 2 times, each 1 ~ 3 hour respectively, and filter, filtrate and supernatant merge, and millipore ultrafilter membrane filters, and filtrate cryoconcentration is to the thick paste of relative density 1.2 ~ 1.8, and viscosity reduction is thick, stirs, and cold drying is extremely done, and porphyrize is for subsequent use; Medical material residue uses 50% ethanol 1 ~ 8 times amount warm macerating 1 ~ 10 day again, and filter, filtrate cryoconcentration is to the thick paste of relative density 1.2 ~ 1.8, and viscosity reduction is thick, stirs, and cold drying is extremely dry, and porphyrize is for subsequent use.
Radix Salviae Miltiorrhizae, Pheretima, Hirudo extract are merged, adds micropowder silica gel 2 ~ 10g, add starch and make into 300g, stir, incapsulate, make 1000, to obtain final product.
1. this product has following features:
1. low dosage
| Medical material title | 2010 editions pharmacopeia using dosages | This prescription using dosage |
| Radix Salviae Miltiorrhizae | 10 ~ 15 grams | 2 grams |
| Hirudo | 1 ~ 3 gram | 0.4 gram |
| Pheretima | 5 ~ 10 grams | 0.4 gram |
This prescription Chinese crude drug using dosage, specifies in Chinese Pharmacopoeia 2010 editions: Radix Salviae Miltiorrhizae consumption 10 ~ 15 grams, Hirudo consumption 1 ~ 3 gram, Pheretima consumption 5 ~ 10 grams.The actual dose of this agent medical material is: Radix Salviae Miltiorrhizae 2 grams (20% ~ 13.3% of pharmacopeia dosage), Hirudo 0.4 gram (40% ~ 13.3% of pharmacopeia dosage), and Pheretima is 0.4 gram (8% ~ 4% of pharmacopeia dosage), is far smaller than the lowest dose level of States Pharmacopoeia specifications, therefore this agent safety.
2. extract at low temperature is dry: adopt modern Chinese medicine extractive technique, utilize freeze thawing technique, dry by extract at low temperature, makes animal drug tissue disruption, is leached by its effective ingredient, keeps the active proteic substance in medical material, improves the bioavailability of this product.
3. high speed centrifugation separation energy removes the material that human body not easily absorbs and needs the absorbent high molecular of enzymolysis conversion, and extract the biological substance be dissolved down in medical material, be beneficial to absorption of human body, onset time is fast.
4. water, alcohol extraction material merge and use, more similar in appearance to the absorption of human body to whole medical material.
5. this agent adopts state-of-the-art millipore membrane separation technique in the world to concentrate, and ensure that homogeneity and the controllability of product.
6. this agent can long-term taking, can avoid the weakness that similar oral formulations should not take for a long time.
2. the reasonability of this product dosage form and the necessity of Clinical practice
1. the reasonability of this kind dosage form: capsule has to be covered medicine and make us uncomfortable bitterness and stink, makes that it is clean and tidy, attractive in appearance, easily swallows; Improve the bioavailability of medicine; Increase medicine stability.This kind adopts No. 0 Caplet, high enrichment, and volume is little, taking convenience, only takes 2 at every turn, takes 2 every day, easy to carry, is easy to keeping.
2. the necessity of this kind Clinical practice
Curative effect advantage: compare with common chemicals: compared with streptokinase, urokinase, heparin, A Sibilin etc., the problems such as hemorrhage recurrence easily appear in these medicines, and administration is inconvenient; Compare with same disease class Chinese patent medicine: huge with veriety prescription, and effect slowly.This prescription prescription keeps TCM Features, forms brief, and drug effect is definite, and taking dose is low, safe and effective.
3. the isolation technics that adopts of this prescription technique, as low temperature, membrance concentration, water containing ethanol extraction share, viscosity reduction is thick, the technology such as cold drying, also do not find in same veriety.Extracting temperature changes the temperature close to human body into, makes the synthetic activity mixture that drug Transformation adult body easily absorbs, so more meets the Chinese medical theory of determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs.Simultaneously due to the reduction of single medical material using dosage in side, product (safety/price) ratio will be caused higher, by the discussion of the closely over thousands of article of single medical material in Gu, Modern Literature the other side, explanation this product is safe and effective, has fully demonstrated the eternal principle of " safely, effectively, economic, reasonable " this medicine development.
3. the economic benefit of this prescription
With the comparison having identical component kind in similar disease kind, this prescription Costco Wholesale cheap 40%, simultaneously this kind rapid-action, have no side effect.
The present invention---three taste blood circulation promoting and blood stasis dispelling capsule pharmacodynamics conclusion (of pressure testing)s
Positive control drug: Xueshuan Xinmaining capsule; Vincamine slow releasing capsule.
Three taste capsules: 0.252g crude drug/kg(low dosage), in 0.504g crude drug/kg(), 1.008g crude drug/kg(is high);
1. the impact of three taste Capsule in Rats middle cerebral artery embolic cerebral ischemic models;
Conclusion: compared with sham operated rats, model control group cerebral ischemia area obviously increases, two groups compare difference significance (
p<0.01).Compared with model control group, three taste capsule 0.504g crude drug/kg, 1.008g crude drug/kg dosage groups, XUESHUANXINMAINING 1.08g/kg dosage group, vincamine slow releasing capsule 10.8mg/kg dosage group cerebral ischemia area obviously reduces, the equal significance of difference (
p<0.05,
p<0.01,
p<0.05,
p<0.01).
2. the impact of three taste Capsule in Rats models of cerebral ischemia-reperfusion injuries;
Conclusion: compared with sham operated rats, model control group SOD vigor obviously reduces, and MDA, NO content obviously raises, two groups compare MDA, NO content difference significance (
p<0.01,
p<0.05).Compared with model control group, three taste capsule 0.504g crude drug/kg, 1.008g crude drug/kg dosage groups, XUESHUANXINMAINING 1.08g/kg dosage group SOD vigor obviously raises, difference significance (
p<0.05,
p<0.05,
p<0.05); MDA, NO content obviously reduces, difference significance (
p<0.05,
p<0.05,
p<0.05).
3. three taste capsules are on mice broken end ischemia model frequency of respiration and the impact of breathing the persistent period;
Conclusion: compared with model control group, three taste capsule 0.364g crude drug/kg, 0.728g crude drug/kg, 1.456g crude drugs/kg dosage group mice pants number of times showed increased, difference significance (
p<0.01,
p<0.01,
p<0.01); Three taste capsule 0.728g crude drug/kg, 1.456g crude drug/kg dosage groups, the XUESHUANXINMAINING 1.56g/kg dosage group mouse breathing persistent period obviously extends, difference significance (
p<0.01,
p<0.05,
p<0.05).
4. three taste capsule mice hypoxia endurance tests;
Conclusion: model control group is compared, three taste capsule 0.364g crude drug/kg, 0.728g crude drug/kg, 1.456g crude drug/kg dosage groups, XUESHUANXINMAINING 1.56g/kg dosage group, there is the effect trend of prolongation the vincamine slow releasing capsule 15.6mg/kg dosage group mouse survival time, but there was no significant difference (
p> 0.05).
5. three taste Capsule in Rats ligation postcava cause thrombotic impact;
Conclusion: compared with model control group, three taste capsule 0.252g crude drug/kg, 0.504g crude drug/kg, 1.008g crude drug/kg dosage groups, XUESHUANXINMAINING 1.08g/kg dosage group, vincamine slow releasing capsule 10.8mg/kg dosage group wet weight of thrombus obviously alleviates, difference significance (
p<0.05,
p<0.05,
p<0.01,
p<0.05,
p<0.05); Three taste capsule 0.504g crude drug/kg, 1.008g crude drug/kg dosage groups, XUESHUANXINMAINING 1.08g/kg dosage group, vincamine slow releasing capsule 10.8mg/kg dosage group thrombosis dry weight obviously alleviates, difference significance (
p<0.05,
p<0.01,
p<0.01,
p<0.05).
6. the impact of the total artery thrombosis of three taste Capsule in Rats To Stimulation of Cervicals;
Conclusion: compared with model control group, three taste capsule 0.504g crude drug/kg, 1.008g crude drug/kg dosage groups, XUESHUANXINMAINING 1.08g/kg dosage group, the average blocking rate that vincamine slow releasing capsule 10.8mg/kg dosage group carotid thrombus is formed obviously reduces, difference significance (
p<0.05,
p<0.01,
p<0.05,
p<0.05).
7. the impact of three taste Capsule on Rabbit Platelets;
Conclusion: compared with blank group, three taste capsule 0.524g crude drugs/kg dosage group platelet aggregation rate obviously reduces, difference significance (
p<0.05).
8. the impact of the experimental blood stasis model hemorheological property of three taste Capsule in Rats;
Conclusion: compare with blank group, model control group whole blood viscosity obviously raises, erythrocyte aggregation index obviously raises, erythrocyte electrophoretic time obviously extends, difference significance (
p<0.001).Compared with model control group, three taste capsule 0.252g crude drug/kg, 0.504g crude drug/kg, 1.008g crude drug/kg dosage groups, XUESHUANXINMAINING 1.08g/kg dosage group, vincamine slow releasing capsule 10.8mg/kg dosage group whole blood viscosity obviously reduces, difference significance (
p<0.001,
p<0.001,
p<0.001,
p<0.001,
p<0.001), erythrocyte aggregation index obviously reduces, difference significance (
p<0.001,
p<0.001,
p<0.001,
p<0.001,
p<0.001), erythrocyte electrophoretic time obviously shortens, difference significance (
p<0.001,
p<0.001,
p<0.001,
p<0.001,
p<0.001).
9. three taste capsules are on the impact of mice Mesentery microcirculation;
Conclusion: compared with blank group, three taste capsule 1.456g crude drug/kg dosage groups average caliber when dripping Ard 2min, 8min obviously increases, difference significance (
p<0.05,
p<0.05); Compared with blank group, three taste capsule 1.456g crude drug/kg dosage groups are before dropping Ard, three taste capsule 0.364g crude drug/kg, 0.728g crude drug/kg, 1.456g crude drug/kg dosage groups, XUESHUANXINMAINING 1.08g/kg dosage group, vincamine slow releasing capsule 10.8mg/kg dosage group is when dripping Ard 2min, three taste capsule 1.456g crude drug/kg dosage groups, XUESHUANXINMAINING 1.08g/kg dosage group, vincamine slow releasing capsule 10.8mg/kg dosage group flow velocity when dripping Ard 8min is accelerated, difference significance (
p<0.01,
p<0.01,
p<0.01,
p<0.001,
p<0.001,
p<0.001,
p<0.001,
p<0.00,
p<0.001); Compared with blank group, three taste capsule 1.456g crude drug/kg dosage groups, XUESHUANXINMAINING 1.08g/kg dosage group, vincamine slow releasing capsule 10.8mg/kg dosage group is when dripping Ard 2min, three taste capsule 1.456g crude drug/kg dosage groups, the fluidised form scoring when dripping Ard 8min of XUESHUANXINMAINING 1.08g/kg dosage group increases, difference significance (
p<0.01,
p<0.01,
p<0.01,
p<0.001,
p<0.001).
Conclusion: three taste capsules have ischemia resisting, antithrombotic, antiplatelet aggregation, improve lectin from hemolymph, improve microcirculatory effect, has protection and therapeutical effect to cerebral infarction.
The acute toxicity test in mice research of the present invention---three taste blood circulation promoting and blood stasis dispelling capsules
Mice maximum administration concentration and maximum administration volume, gastric infusion 1 time in 1 day, dosage is 51.84g crude drug/kg, this dosage is about 1036 times (adult's body weight is by 60kg) of adult's oral dose every day, animal, without death, is observed 14 days, has no overt toxicity reaction.Animal carries out gross anatomy after the observation period terminates, the main organs such as the perusal heart, liver, spleen, lung, kidney, and no abnormality seen changes.
The present invention---three taste blood circulation promoting and blood stasis dispelling Capsules on Rats long term toxicity test research data and documents and materials
Three taste capsule successive administrations 6 months, the rat mental status, autonomic activities Non Apparent Abnormality, high dose group food ration reduces to some extent, but rat body weight increases all normal, there was no significant difference (P>0.05) is compared with blank group, point out long-time this medicine of heavy dose of gavage, rat food ration may be affected, but growth promoter (body weight growth) avirulence of rat is affected.After drug withdrawal, rat food ration recovers normal.
Three taste capsule successive administrations 3 months and 6 months, each dosage group P of Rats T obviously extends, and in dosage ~ reaction relation, drug withdrawal recovers normal after 4 weeks, point out this drug on coagulation system to have impact, this is consistent with the pharmacodynamic action of this medicine.
Three taste capsule successive administrations 6 months, high dose group rat chlorine ion concentration reduces, and drug withdrawal recovers normal after 4 weeks, point out this medicine may have impact to chloride ion metabolism, can recover after drug withdrawal.High dose group male rat AST, CK obviously reduce (P<0.01), though drug withdrawal made moderate progress (P<0.05) after 4 weeks, but still can not recover normal, point out this medicine may have impact to buck myocardium enzyme, drug withdrawal is not enough to recover for 4 weeks, advises the monitoring should strengthened in clinical trial these indexs.
Three taste capsule successive administrations 3 months, 6 months and drug withdrawal are after 4 weeks, gross necropsy main organs outward appearance and tangent plane, be showed no obvious pathological changes, each organ coefficient, without obvious change, is fixed through 10% formalin, pathology routine is drawn materials film-making, HE dyes, light Microscopic observation, and histological indications shows, the each organs and tissues of blank group rat Histological change without exception, each organs and tissues of administration high dose group rat is learned without drug-induced abnormal structure and is changed.
Conclusion: three taste Capsules on Rats gastric infusion safe doses are 2.90g crude drug/below kg, is about 61.70 times (adult is by 60kg weighing machines) that clinical adult intends consumption.
The present invention---the healing case of three taste blood circulation promoting and blood stasis dispelling capsules
Case one-yellow ××: identification card number: 2310031938 ××××s 1621;
Date of the onset: in July, 2006;
Case diagnosis: left large and small lower limb, deep venous thrombosis;
Body surface needle-like: morbidity lower limb and normal lower limb ratio nearly greatly 50%, edema of lower limbs, pain;
Therapeutic scheme: stop using after drop urokinase on the 2nd, change and take this product;
Taking dose: every day 3 times, each 3, after taking 1 month, body surface is tending towards normal, takes after 3 months and cures, now by prophylactic treatment consumption daily this medicine, take 7 years continuously, then do not fall ill.
Case two---Zhao's ××: identification card number: 2301031995 ××××s 0066;
Date of the onset: in January, 2009;
Case diagnosis: non-ossifying fibroma, except chondroma;
Body surface symptom: shank obviously has projection, has pain.
Therapeutic scheme: take this product;
Taking dose: first month is every day 3 times, each 2, the dosage taken after one month is every day 2 times, each 2, cures, drug withdrawal after 2 months.
Claims (8)
1. the preparation method of three taste blood circulation promoting and blood stasis dispelling capsules, is characterized in that, by weight, comprise the following steps:
(1), get Radix Salviae Miltiorrhizae 300 ~ 700 parts, 12 ~ 24 times amount that add water are extracted, and filter, are concentrated into the clear paste of relative density 1.0 ~ 1.5, add ethanol 2.4 ~ 4.8 times amount, stir, and leave standstill 24 ~ 72 hours, get supernatant, reclaim ethanol and are dried to dry, porphyrize, for subsequent use;
(2), each 80 ~ 120 parts of water intaking trematodiasis, Pheretima add 1 ~ 10 times amount normal saline respectively and soak, and be ground into homogenate, freeze-thaw is extracted, and filters or centrifugal, and filtrate is for subsequent use; Residue extracting in water, filter, filtrate and supernatant merge, and ultrafilter membrane filters, and be concentrated into the thick paste of relative density 1.2 ~ 1.8, viscosity reduction is thick, stirs, and be dried to dry, porphyrize is for subsequent use; Medical material residue is again with ethanol 1 ~ 8 times amount leaching 1 ~ 10 day, and filter, filtrate is concentrated into the thick paste of relative density 1.2 ~ 1.8, and viscosity reduction is thick, stirs, and is dried to dry, porphyrize, for subsequent use;
(3), by Radix Salviae Miltiorrhizae, Pheretima, Hirudo extract merge, add micropowder silica gel 2 ~ 10 parts, add starch and make into 200 ~ 400 parts, stir, incapsulate, to obtain final product.
2. the preparation method of three taste blood circulation promoting and blood stasis dispelling capsules as claimed in claim 1, is characterized in that, in step (1), extracting in water is 2 times, and add water 6 ~ 12 times amount at every turn, extracts 1 ~ 5 hour.
3. the preparation method of three taste blood circulation promoting and blood stasis dispelling capsules as claimed in claim 1, is characterized in that, in step (1), mixing time is 10 ~ 50 minutes.
4. the preparation method of three taste blood circulation promoting and blood stasis dispelling capsules as claimed in claim 1, is characterized in that, in step (2), Hirudo, Pheretima add 1 ~ 10 times amount normal saline respectively and soak, and continue and add normal saline 2 times amount, be ground into homogenate.
5. the preparation method of three taste blood circulation promoting and blood stasis dispelling capsules as claimed in claim 1, is characterized in that, after being ground into homogenate in step (2), jolting is extracted 1 ~ 12 hour.
6. the preparation method of three taste blood circulation promoting and blood stasis dispelling capsules as claimed in claim 1, is characterized in that, in step (2), freeze-thaw is extracted, and leaves standstill 1 ~ 12 hour.
7. the preparation method of three taste blood circulation promoting and blood stasis dispelling capsules as claimed in claim 1, is characterized in that, residue 1 ~ 5 times amount that adds water extracts 2 times, each 1 ~ 3 hour respectively in step (2).
8. the preparation method of three taste blood circulation promoting and blood stasis dispelling capsules as claimed in claim 1, is characterized in that, 50% ethanol 1 ~ 8 times amount lixiviate 1 ~ 10 day of step (2) Chinese crude drug residue.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310348295.7A CN103405501B (en) | 2013-08-12 | 2013-08-12 | Preparation method of three-component blood-activating and stasis-dissolving capsules |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310348295.7A CN103405501B (en) | 2013-08-12 | 2013-08-12 | Preparation method of three-component blood-activating and stasis-dissolving capsules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103405501A CN103405501A (en) | 2013-11-27 |
| CN103405501B true CN103405501B (en) | 2015-04-22 |
Family
ID=49598575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310348295.7A Active CN103405501B (en) | 2013-08-12 | 2013-08-12 | Preparation method of three-component blood-activating and stasis-dissolving capsules |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103405501B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110483635A (en) * | 2019-08-23 | 2019-11-22 | 王世生 | Induce liquid and preparation method thereof and hirudin/Lumbrokinase extracting method and hirudin Lumbrokinase oral solution and its preparation method and application |
| CN111481601A (en) * | 2020-04-15 | 2020-08-04 | 湖南省中医药研究院 | Medicine for treating cerebral apoplexy and construction method of endogenous stem cell expression animal model |
| CN112656883B (en) * | 2020-12-21 | 2022-01-28 | 黑龙江儒泰科技发展有限责任公司 | Traditional Chinese medicine composition for treating ischemic cerebrovascular disease and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1281719A (en) * | 1999-07-26 | 2001-01-31 | 王淑清 | Chinese medicine composition for curing ischemic angiocardiopathy and cerebrovascular disease and its preparation method |
| CN1279950C (en) * | 2005-03-01 | 2006-10-18 | 中国人民解放军第四军医大学药物研究所 | Compound formula earthworm capsule and its preparation technology |
| CN101095697A (en) * | 2006-06-28 | 2008-01-02 | 李振国 | Extractive of bdella and/or lumbricus with the molecular weight below 5800 dalton |
| CN102178697B (en) * | 2011-04-26 | 2013-01-02 | 李双阳 | Compound leech capsule and preparation method thereof |
-
2013
- 2013-08-12 CN CN201310348295.7A patent/CN103405501B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103405501A (en) | 2013-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102600423B (en) | Preparation method of Chinese medicine for treating hepatic fibrosis | |
| CN1327876C (en) | Chinese drugs compositions for treating diabetes and its complications | |
| CN103405501B (en) | Preparation method of three-component blood-activating and stasis-dissolving capsules | |
| CN105412410A (en) | Traditional Chinese medicine preparation for preventing and treating radiographic contrast nephropathy | |
| CN102885307B (en) | Composition for damp-heat constitutions, preparation method and applications thereof | |
| CN103893283B (en) | A kind of Chinese medicine composition for treating chronic kidney disease and chronic kidney hypofunction and preparation method thereof | |
| CN101849987A (en) | Preparation of Chinese angelica and astragalus root mixture ethanol extract and aqueous extract and application in intervening in pulmonary fibrosis | |
| CN101822729B (en) | Medicine for treating slow arrhythmia sick sinus syndromes | |
| CN105434738A (en) | Traditional Chinese medicine composition for treating ADHD (Attention Deficit Hyperactivity Disorder) and preparation method thereof | |
| CN102988461B (en) | A kind of gadol injection and preparation method thereof | |
| CN109224038A (en) | A kind of Chinese medicine composition of the evodia rutaecarpa containing guiding drug and its preparation method and application for treating obstruction of collaterals by blood stasis type liver fibrosis | |
| CN100563647C (en) | The Pharmaceutical composition of Herba Erigerontis and sodium tanshinon IIA silate injection | |
| CN106822382A (en) | The preparation method and application of Cheng forture paulownia root n-butanol extract | |
| CN115120689A (en) | Application of Xinli rehabilitation formula preparation in preparation of medicines | |
| CN103705772B (en) | Chinese medicine composition that a kind of antiinflammatory protects the liver and preparation method thereof | |
| CN103893286B (en) | It is a kind of to treat Chinese medicine preparation of chronic renal disease and preparation method thereof | |
| CN103549072B (en) | Vital energy-benefiting brain-boosting tea and preparation method thereof | |
| CN106728447A (en) | The preparation method and application of Cheng forture paulownia root ethyl acetate extract | |
| CN106138464A (en) | A kind of preparation method of emphysema capsule | |
| CN102389449B (en) | Erigeron breviscapus extract and preparation method and application thereof | |
| CN1899352B (en) | Chinese medicine effective part composition for supplementing qi and recovering pulse | |
| CN103238834A (en) | Composition for treating cutaneous pruritus and preparation method of composition | |
| CN113995791B (en) | Gynura procumbens compound medicine capable of benefiting qi, nourishing blood, and preventing and treating anemia and preparation method and application thereof | |
| CN102716231A (en) | Traditional Chinese medicinal composition for treating brain damage and brain edema and application thereof | |
| CN100333751C (en) | Chinese traditional medicine for curing cholestatic hepatitis and preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |